A Molecular Basis for Nicotine As a Gateway Drug
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs
SMOKING CEssATION TREATMENT AT SUBSTANCE ABUSE REHABILITATION PROGRAMS Malcolm S. Reid, PhD, New York University School of Medicine, Department of Psychiatry; Jeff Sel- zer, MD, North Shore Long Island Jewish Healthcare System; John Rotrosen, MD, New York University School of Medicine, Department of Psychiatry Cigarette smoking is common among persons with drug and alcohol n Nicotine is a highly use disorders, with prevalence rates of 80-90% among patients in sub- addictive substance stance use disorder treatment programs. Such concurrent smoking may that meets all of produce adverse behavioral and medical problems, and is associated the criteria for drug with greater levels of substance use disorder. dependence. CBehavioral studies indicate that the act of cigarette smoking serves as a cue for drug and alcohol craving, and the active ingredient of cigarettes, nicotine, serves as a primer for drug and alcohol abuse (Sees and Clarke, 1993; Reid et al., 1998). More critically, longitudinal studies have found tobacco use to be the number one cause of preventable death in the United States, and also the single highest contributor to mortality in patients treated for alcoholism (Hurt et al., 1996). Nicotine is a highly addictive substance that meets all of the criteria for drug dependence, and cigarette smoking is an especially effective method for the delivery of nicotine, producing peak brain levels within 15-20 seconds. This rapid drug delivery is one of a number of common properties that cigarette smok- ing shares with hazardous drug and alcohol use, such as the ability to activate the dopamine system in the reward circuitry of the brain. -
Alcohol, Tobacco, and Prescription Drugs: the Relationship with Illicit Drugs in the Treatment of Substance Users
Macquarie University ResearchOnline This is the author version of an article published as: Teesson, M., Farrugia, P., Mills, K., Hall, W., & Baillie, A. (2012). Alcohol, tobacco, and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Substance use & misuse, Vol. 47, Issue 8-9, p. 963-971. Access to the published version: http://doi.org/10.3109/10826084.2012.663283 Copyright: Copyright the Publisher 2012. Version archived for private and non- commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher. Comorbidity 1 Alcohol, tobacco and prescription drugs: The relationship with illicit drugs in the treatment of substance users. Maree Teesson, Philippa Farrugia, Katherine Mills 1 Wayne Hall2, Andrew Baillie3. 1. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales 2052 Australia, 2. University of Queensland Centre for Clinical Research, 3. Centre for Emotional Health, Department of Psychology, Macquarie University. * Corresponding author: Maree Teesson National Drug and Alcohol Research Centre University of New South Wales, Sydney New South Wales 2052 Australia Tel: +61 2 9385 0333; fax: +61 2 9385 0222; email: [email protected] Abstract Alcohol, tobacco, prescription drug and illicit drug use frequently co-occur. This paper reviews the extent of this co-occurrence in both general population samples and clinical samples, and its impact on treatment outcome. We argue that the research base for understanding comorbidity between tobacco, alcohol, prescription and illicit drugs needs to be broadened. We specifically advocate for: 1) more epidemiological studies of relationships between alcohol, tobacco and other illicit drug use; and 2) increased research on treatment options that address the problematic use of all of these drugs. -
Concurrent Alcohol and Tobacco Dependence
Concurrent Alcohol and Tobacco Dependence Mechanisms and Treatment David J. Drobes, Ph.D. People who drink alcohol often also smoke and vice versa. Several mechanisms may contribute to concurrent alcohol and tobacco use. These mechanisms include genes that are involved in regulating certain brain chemical systems; neurobiological mechanisms, such as cross-tolerance and cross-sensitization to both drugs; conditioning mechanisms, in which cravings for alcohol or nicotine are elicited by certain environmental cues; and psychosocial factors (e.g., personality characteristics and coexisting psychiatric disorders). Treatment outcomes for patients addicted to both alcohol and nicotine are generally worse than for people addicted to only one drug, and many treatment providers do not promote smoking cessation during alcoholism treatment. Recent findings suggest, however, that concurrent treatment for both addictions may improve treatment outcomes. KEY WORDS: comorbidity; AODD (alcohol and other drug dependence); alcoholic beverage; tobacco in any form; nicotine; smoking; genetic linkage; cross-tolerance; AOD (alcohol and other drug) sensitivity; neurotransmitters; brain reward pathway; cue reactivity; social AODU (AOD use); cessation of AODU; treatment outcome; combined modality therapy; literature review lcohol consumption and tobacco ers who are dependent on nicotine Department of Health and Human use are closely linked behaviors. have a 2.7 times greater risk of becoming Services 1989). The concurrent use of A Thus, not only are people who alcohol dependent than nonsmokers both drugs by pregnant women can drink alcohol more likely to smoke (and (e.g., Breslau 1995). Finally, although also result in more severe prenatal dam- vice versa) but also people who drink the smoking rate in the general popula age and neurocognitive deficits in their larger amounts of alcohol tend to smoke tion has gradually declined over the offspring than use of either drug alone more cigarettes. -
Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul stance use was considered a potential the most common substance use nerability may be located on chromo trigger for the primary addiction. -
ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update
The ASAM NATIONAL The ASAM National Practice Guideline 2020 Focused Update Guideline 2020 Focused National Practice The ASAM PRACTICE GUIDELINE For the Treatment of Opioid Use Disorder 2020 Focused Update Adopted by the ASAM Board of Directors December 18, 2019. © Copyright 2020. American Society of Addiction Medicine, Inc. All rights reserved. Permission to make digital or hard copies of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for commercial, advertising or promotional purposes, and that copies bear this notice and the full citation on the fi rst page. Republication, systematic reproduction, posting in electronic form on servers, redistribution to lists, or other uses of this material, require prior specifi c written permission or license from the Society. American Society of Addiction Medicine 11400 Rockville Pike, Suite 200 Rockville, MD 20852 Phone: (301) 656-3920 Fax (301) 656-3815 E-mail: [email protected] www.asam.org CLINICAL PRACTICE GUIDELINE The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update 2020 Focused Update Guideline Committee members Kyle Kampman, MD, Chair (alpha order): Daniel Langleben, MD Chinazo Cunningham, MD, MS, FASAM Ben Nordstrom, MD, PhD Mark J. Edlund, MD, PhD David Oslin, MD Marc Fishman, MD, DFASAM George Woody, MD Adam J. Gordon, MD, MPH, FACP, DFASAM Tricia Wright, MD, MS Hendre´e E. Jones, PhD Stephen Wyatt, DO Kyle M. Kampman, MD, FASAM, Chair 2015 ASAM Quality Improvement Council (alpha order): Daniel Langleben, MD John Femino, MD, FASAM Marjorie Meyer, MD Margaret Jarvis, MD, FASAM, Chair Sandra Springer, MD, FASAM Margaret Kotz, DO, FASAM George Woody, MD Sandrine Pirard, MD, MPH, PhD Tricia E. -
Drug Use Sequencing and Kandel's Gateway Hypothesis John Reid Clemson University, [email protected]
Clemson University TigerPrints All Theses Theses 8-2008 Drug Use Sequencing and Kandel's Gateway Hypothesis John Reid Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_theses Part of the Sociology Commons Recommended Citation Reid, John, "Drug Use Sequencing and Kandel's Gateway Hypothesis" (2008). All Theses. 447. https://tigerprints.clemson.edu/all_theses/447 This Thesis is brought to you for free and open access by the Theses at TigerPrints. It has been accepted for inclusion in All Theses by an authorized administrator of TigerPrints. For more information, please contact [email protected]. DRUG USE SEQUENCING AND KANDEL'S GATEWAY HYPOTHESIS A Thesis Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Master of Science Applied Sociology by John Matthew Reid August 2008 Accepted by: Dr. Brenda Vander Mey, Committee Chair Dr. Douglas Kinly Sturkie Dr. Margaret Tina Britz i ABSTRACT This thesis tests the hypothesis by Kandel (1975) that there is a specific sequence of drug use that users follow. Using the same scalogram analysis technique utilized by Kandel in her original Gateway Hypothesis study, a distinct sequence of use was discovered. This thesis is based on the National Survey on Drug Use and Health (2005). This study confirmed Kandel’s earlier findings in that this study determined that there is a sequence of drug use. The current study also confirms Kandel’s position that licit drugs precede the use of illicit drugs. This study’s findings differ from those of Kandel, however, in that tobacco and not alcohol was found to be the first drug of experimentation. -
Evidence-Based Guidelines for the Pharmacological Management of Substance Abuse, Harmful Use, Addictio
444324 JOP0010.1177/0269881112444324Lingford-Hughes et al.Journal of Psychopharmacology 2012 BAP Guidelines BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, Journal of Psychopharmacology 0(0) 1 –54 harmful use, addiction and comorbidity: © The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalsPermissions.nav recommendations from BAP DOI: 10.1177/0269881112444324 jop.sagepub.com AR Lingford-Hughes1, S Welch2, L Peters3 and DJ Nutt 1 With expert reviewers (in alphabetical order): Ball D, Buntwal N, Chick J, Crome I, Daly C, Dar K, Day E, Duka T, Finch E, Law F, Marshall EJ, Munafo M, Myles J, Porter S, Raistrick D, Reed LJ, Reid A, Sell L, Sinclair J, Tyrer P, West R, Williams T, Winstock A Abstract The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people. Keywords Substance misuse, addiction, guidelines, pharmacotherapy, comorbidity Introduction guidelines (e.g. -
Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender
Opioid and Nicotine: Influences of Sex and Gender Conference Report: Opioid and Nicotine Use, Dependence, and Recovery: Influences of Sex and Gender Authors: Bridget M. Nugent, PhD. Staff Fellow, FDA OWH Emily Ayuso, MS. ORISE Fellow, FDA OWH Rebekah Zinn, PhD. Health Program Coordinator, FDA OWH Erin South, PharmD. Pharmacist, FDA OWH Cora Lee Wetherington, PhD. Women & Sex/Gender Differences Research Coordinator, NIH NIDA Sherry McKee, PhD. Professor, Psychiatry; Director, Yale Behavioral Pharmacology Laboratory Jill Becker, PhD. Biopsychology Area Chair, Patricia Y. Gurin Collegiate Professor of Psychology and Research Professor, Molecular and Behavioral Neuroscience Institute, University of Michigan Hendrée E. Jones, Professor, Department of Obstetrics and Gynecology; Executive Director, Horizons, University of North Carolina at Chapel Hill Marjorie Jenkins, MD, MEdHP, FACP. Director, Medical Initiatives and Scientific Engagement, FDA OWH Acknowledgements: We would like to acknowledge and extend our gratitude to the meeting’s speakers and panel moderators: Mitra Ahadpour, Kelly Barth, Jill Becker, Kathleen Brady, Tony Campbell, Marilyn Carroll, Janine Clayton, Wilson Compton, Terri Cornelison, Teresa Franklin, Maciej Goniewcz, Shelly Greenfield, Gioia Guerrieri, Scott Gottlieb, Marsha Henderson, RADM Denise Hinton, Marjorie Jenkins, Hendrée Jones, Brian King, George Koob, Christine Lee, Sherry McKee, Tamra Meyer, Jeffery Mogil, Ann Murphy, Christine Nguyen, Cheryl Oncken, Kenneth Perkins, Yvonne Prutzman, Mehmet Sofuoglu, Jack Stein, Michelle Tarver, Martin Teicher, Mishka Terplan, RADM Sylvia Trent-Adams, Rita Valentino, Brenna VanFrank, Nora Volkow, Cora Lee Wetherington, Scott Winiecki, Mitch Zeller. We would also like to thank those who helped us plan this program. Our Executive Steering Committee included Ami Bahde, Carolyn Dresler, Celia Winchell, Cora Lee Wetherington, Jessica Tytel, Marjorie Jenkins, Pamela Scott, Rita Valentino, Tamra Meyer, and Terri Cornelison. -
2016 and Over 4,000 Research Scientists, 168 Scientific Leaders and 60,000 Was Our Leader and Guiding Light, Providing Inspiration and Moti- Pression
INVEST IN MENTAL HEALTH ANNUAL REPORT 2 0 1 6 Dear Brain & Behavior Research Foundation Supporters: From mental illness to mental health–30 years of achievements by tremendous impact on psychiatric research and treatment. Connie problems improves symptoms of some patients with refractory de- The Foundation is proud of our accomplishments in 2016 and over 4,000 research scientists, 168 scientific leaders and 60,000 was our leader and guiding light, providing inspiration and moti- pression. In a study of patients with treatment-resistant depression, we are excited to focus on the promising path of discovery. With donors. We are proud to present you with our 2016 annual report vation to all who ever had the honor and privilege of knowing and about two thirds had metabolic deficiencies that affect the brain’s your sustained commitment, we will accelerate the funding of our and invite you to invest in mental health. working with her. She will be dearly missed by us all. But her legacy ability to produce neurotransmitters. Dr. Pan’s research found Grants and continue to lead the field with breakthroughs that continues with each new scientist which we support and each new that patients’ depression symptoms declined significantly when improve the lives of those living with mental illness. Thank you for Since 1987, the Brain & Behavior Research Foundation has invest- discovery which improves people’s lives. their metabolic problems were treated. Some of the patients even continuing the journey with us. ed in the future. We support the innovative brain and behavior reached remission. The most common of the deficiencies observed research today which will lead to new treatments and eventual While we are proud of our accomplishments, there is still much in the participants was in levels of cerebral folate, which is treat- Sincerely, cures in the future. -
Transcriptome Sequencing Reveals Candidate NF-Κb Target Genes Involved in Repeated Cocaine Administration Yan Wang, Huajing Teng, Daniel M
Copyedited by: oup International Journal of Neuropsychopharmacology (2018) 21(7): 697–704 doi:10.1093/ijnp/pyy031 Advance Access Publication: March 21, 2018 Regular Research Article regular research article Transcriptome Sequencing Reveals Candidate NF-κB Target Genes Involved in Repeated Cocaine Administration Yan Wang, Huajing Teng, Daniel M. Sapozhnikov, Quansheng Du, Mei Zhao Key Lab of Mental Health, Institute of Psychology, Chinese Academy of Sciences, China (Drs Wang and Zhao); University of Chinese Academy of Sciences, Beijing, China (Drs Wang, Teng, and Zhao); Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing China (Dr Teng); Department of Pharmacology and Therapeutics, McGill University Montreal, Quebec, Canada (Mr Sapozhnikov); Department of Life Sciences, National Natural Science Foundation of China, Beijing, China (Dr Du). Correspondence: Dr. Mei Zhao, 16 Lincui Road, Chao Yang District, Beijing 100101, China ([email protected]). Abstract Background: Drug-induced alterations in gene expression play an important role in the development of addictive behavior. Numerous transcription factors have been implicated in mediating the gene expression changes that occur in drug addiction. Nuclear factor kappa B is an inducible transcription factor complex that is rapidly activated by diverse stimuli. Methods: We performed next-generation high-throughput sequencing of the prefrontal cortex in a mouse model of repeated cocaine administration combined with pharmacological nuclear factor kappa B inhibition to identify nuclear factor kappa B target genes that participate in the cocaine addiction process. Results: We found that the nuclear factor kappa B antagonist sodium diethyldithiocarbamate trihydrate significantly reversed the cocaine-induced expression changes of the amphetamine addiction pathway. Genes that demonstrated differential expression in response to cocaine treatment that was also reversed by sodium diethyldithiocarbamate trihydrate were enriched for the axon guidance pathway. -
Therapy Manuals for Drug Addiction. Manual 1
i ACKNOWLEDGMENTS The development of earlier versions of this manual was supported by several research grants from the National Institute on Drug Abuse. The current manual was written by Dr. Kathleen Carroll of Yale University under Contract Number N-OIDA-4-2205 with the National Institute on Drug Abuse. Dr. Lisa Onken, the NIDA Project Officer, offered valuable guidance and comments throughout the preparation of this manual. The material presented in this manual is the result of a program of research by Dr. Kathleen Carroll and Dr. Bruce Rounsaville and their colleagues at Yale University. The development of this therapy model for treatment of drug abuse drew extensively from the work of Alan Marlatt and others (Marlatt and Gordon 1985; Chancy et al. 1978; Jaffe et al. 1988; Ito et al. 1984). The structure and sequence of sessions presented in this therapy model was partially developed by work on Project MATCH published by the National Institute on Alcohol Abuse and Alcoholism (Kadden et al. 1992) and the manual developed by Peter Monti and his colleagues (1989). These sources are particularly reflected here in the a skills-training material, and we have acknowledged the original sources in each of those sections. Yale University Research Team Coinvestigators: Bruce Rounsaville, M.D. Roseann Bisighini, M.S. Charla Nich, M.S. Monica Canning-Ball Sam Ball, Ph.D. Joanne Corvino, M.P.H. Lisa Fenton, Psy.D. Kea Cox Frank Gawin, M.D. Lynn Gordon, R.N. Tom Kosten, M.D. Tami Frankforter Elinor McCance-Katz, M.D., Ph.D. jenniffer Owler Douglas Ziedonis, M.D. -
Substance Abuse by Adolescents in 1977 with 499 French Adolescents
In a country like Israel, which is deeply committed to the main sources of infection, among them active foci achievement of an expanded immunization program, the still present in the neighboring territories. effort to reach this objective should be weighed within the national program aimed at elimination of the diseases References .................................. controlled by mass immunization. Analysis of present achievements clearly shows that measles, together with 1. Swartz, T. A., and Klingberg, W.: Routine measles immu- poliomyelitis and rubella, deserves to be included among nization in Israel: A three-year clinical and serologic follow- up. In International conference on application of vaccines the first priorities of a program whose objective is elim- against viral, rickettsial, and bacterial diseases of man, ination of clinical disease. Washington, D.C., 14-18 December 1970. Pan American Health Organization, Washington, D.C., 1971, pp. Conclusions 265-268. 2. Centers for Disease Control: Measles Surveillance Report No. 11, 1977-1981. Atlanta, Ga., September 1982. A 17-year-old immunization program has created the 3. Health and Welfare Canada: Measles in Canada. Canada basis for elimination of measles in Israel, provided that Diseases Weekly Report 9-25: 29-101 (1983). (a) the control policy is adapted to the seroepidemiology 4. World Health Organization: Measles surveillance. Weekly of the infection, and (b) a concentrated logistic effort is Epidemiol Record 58: 85-86 (1983). mounted in the period preceding the next expected epi- 5. Hopkins, D. R., Hinman, A. R., Kaplan, J. E, and Lane, J. M.: The case for global measles eradication. Lancet 1: demic. Under this effort: 1936-1938, June 19, 1982.